PATHOLOGISTS have recognized for many years that two important factors in the prognosis of malignant lymphoma are the size of the neoplastic cells and the presence or absence of a follicular pattern. Tumours composed of small cells or possessing a follicular structure occupy the benign end of a spectrum of malignancy. Despite the looseness of definition and the profound effects of fixation on cell size, there is a general awareness that the old terms "reticulum cell sarcoma" and "histiocytic tumour" refer to large-cell neoplasms. Today there is a tendency to have within this category a number of subgroups which have arisen from defined cells found in the germinal centres of lymphoid tissue. These are:
(1) Large centrocytes: these cells have an irregular nuclear outline, an inconspicuous nucleolus and abundant cytoplasm. They are common in reactive follicle centres hut less so in neoplasms.
(2) Centroblasts: the nuclei are about the same size as those of macrophages and are round and vesicular. They have up to 4 nucleoli, often close to the nuclear membrane, and a thin rim of pyroninophilic cytoplasm.
(3) Immunoblasts: these are found in the germinal centres and also in the interfollicular areas of lymphoid tissue. The nucleolus is usually single and central and the cytoplasm is strongly pyroninophilic. They may show plasmacytoid differentiation (plasmablastic).
These cell types give rise to 3 recognizable morphological subgroups of neoplasm; i.e.
(1) large centrocytic, (2) A fourth group, still controversial and awaiting further research with marker studies, is thought to be composed of large neoplastic histiocytes. At present these are rarely recognized.
In addition, tumours composed of pleomorphic large and multinucleated giant cells which defy precise categorization are en- countered. Some of these may prove to be epithelial or mesenchymal in origin. Thus, we have 5 subgroups of large-cell tumour which can be recognized by the hospital pathologist using a light microscope and routine staining procedures. When marker studies are added, some of these groups can often be shown to be derived from B or T lymphocytes.
These large-cell tumours, with the exception of the large centrocytic type, are highly aggressive and pose a challenge to all concerned with their management. An important contribution to this management may rest with clear recognition of the tumour subtvpes.
SURFACE PHENOTYPES OF LARGE-CELL LYMPHOMA
A. J. HABESHAW From the Department of Medical Oncology, St Bartholomew's Hospital, London EC1A 7BE LARGE-CELL LYMPHOMAS (LCL) form a heterogeneous group which poses a continuing diagnostic problem. This summary documents the result of attempts to define these tumours by surface phenotype in the hope of identifying the groups with good and bad prognosis, since about one third of patients with LCL show significant long-term survival with present modes of treatment.
Using the Kiel classification, large-cell lymphomas fall into the groups (1) immunoblastic lymphoma, (2) centroblastic lymphoma, (3) high grade unclassified. Centrocytic tumours of large-cell type are usually regarded as large-cell lymphomas. These categories are equivalent to DHL of Rappaport. The "high grade unclassified" group is quite distinct from the category of unclassified "lymphoblastic lymphoma". The data reported here are concerned with patients whose histological diagnoses were of immunoblastic lymphoma (MLIB, 11 cases) , centroblastic lymphoma (MLCB, 4 cases), malignant lymphoma of high grade unclassified (MLHgU, 6 cases), centrocytic lymphoma of large cell type (MLCC/LC, 2 cases) and malignant histiocytosis (MH, 1 case).
The phenotyping was always performed on fresh viable cells obtained on surgical biopsy of lymph node or tumour mass. In each case the suspension was tested for E rosettes, Fcy and Fc, rosettes, C3d rosettes, surface and cytoplasmic immunoglobulin. Antisera specific for T cells (HTLA) and anti-Ia (HLA D) were used in some cases. Phagocytes were quantitated by their Neutral Red uptake. The phenotypic profile was obtained and evaluated independently of the histological Table I ). The phenotype of the patients with B-cell lymphoma are shown in Table II . High-grade B-cell lymphomas show non-capping surface Ig, a feature related to survival (Figure) T-cell tumours were present in 6 patients with LCL lymphoma (Table III) . Of these, 3 w%Nere histologically classified as MLIB, 1 as MLCB, and 2 as MLHgU. The numbers of accompanying B cells in these cases varied from 3%0 to 30,0o with no evidence of B-cell monoclonalitv. Four cases tested for TdT proved negative, establishing that these T-cell neoplasms are not derived from immature precursors, but from peripheralized mature TH or Ts subsets. All 6 patients with high-grade T-cell lymphoma have died, the longest survival in this group being about 300 days.
Tumours containing many functional mononuclear phagocytes (Table IV) (1) Substantial numbers of functional phagocytes.
(2) Fcy receptor on > 25 % of cells. Of the 4 cases meeting these criteria, 2 were diagnosed as MLHgU, one as MLIB, and one as MH. Null-cell tumours occurred in 3 cases (Table V) . Null-cell tumours are lymphomas with none of the established features of B cells, T cells or mononuclear phagocytes.
The tumour cells may exhibit Fey or C3d receptors, but are not obviously phagocytic. In patient M, the presenting feature was hypogammoglobulinaemia. All patients with null-cell tumours had nodal presentations of light-chain isotype. Such a finding is most uncommon in LCL of the B series, and when it is present it is difficult to be certain that the cells in the blood are precursors of those in the solid tumour, they might be derived from the tumour itself. In some situations where recirculating precursors are present with high-grade LCL, it seems probable that a highly malignant large-cell clone has appeared in a multi-differentiation-stage lymphoma of low malignancy. This situation, analogous to that of blast crisis of chronic granulocytic leukaemia, is a well recognized complication of follicle-centre-cell tumour, i.e. mixed centroblastic/centrocytic lymphomas of low malignancy may give rise to highly malignant immunoblastic lymphoma. Also in myelomatosis, where the disease is usually strictly confined to the marrow or periosteal sites, immunoblastoma which forms secondary extramedullary deposits may occur. Whether all "multistage" LCL are of this type remains to be determined. In such cases eradication of the highly malignant subelone will not necessarily eliminate the parental low-grade lymphoma.
There The opportunity therefore arises to use lectins to study the behaviour of different lymphomas within the body. Lymphocyte imaging, using radioactive indium-ill oxine can trace the circulation of lymphocytes through the organs of the body (Wagstaff et al., 1981) . The predisposition of some lymphomas to present in extra-nodal sites (Blackledge et al., 1980b) and to have characteristic behaviour patterns of spread and prognosis, may be, in part, explained by the abnormal surface glycoproteins detected by lectin binding.
Further studies are under way using a wider range of lectins to examine these phenomena.
NON-RANDOM CHROMOSOME INVOLVEMENT IN NON-BURKITT,
NON-HODGKIN LYMPHOMA K. L. GAUNT From the Department of Human Genetics, University of Newcastle upon Tyne CHROMOSOMAL ANALYSIS of lymph-node biopsies from patients with suspected malignant lymphoma was undertaken. Six of these yielded abnormal banded karyotypes. There were 4 males and 2 females, 3 with a follicular lymphoma and 3 with a LCL. Full karyotype analysis of the abnormal clones was obtained for 5 patients; these had a modal chromosome number of 45-48. In the 6th patient the abnormal clone tended towards tetraploidy, and although several consistent chromosome markers were seen, no full cell was karyotyped. Numerical and structural abnormalities were found in all cases. In the 5 patients with full karyotype analysis, chromosome 7 was gained in 3 cases and the Y chromosome was lost in 2 of the 4 male patients.
Structurally, the chromosome most affected was chromosome 9, altered in 4 cases. Chromosomes 1, 6 and 14 were altered in 3 of the patients and chromosomes 3, 7, 11 and 18 in 2 cases.
The position of the chromosome breakpoints involved in deletions and translocations was also non-random. The centromere region of chromosome 1 was involved in 4/7 breaks; the centromere and distal terminal band of chromosome 3 in 2/5 rearrangements, the distal terminal band of chromosome 9 in 3/4 rearrangements and the distal terminal band of chromosome 14 in all 3 cases of structural rearrangements of that chromosome.
Two patients, a 45-year-old female with a follicular lymphoma of small-cell type and an 85-year-old female with a follicular lymphoma of small and large cells, had similar marker chromosomes; the first case had a derivative chromosome 9, t(9;1 ;1) (9pter-->9q 34: :lpter -l>1p32::1q11-1qter) with a del l(p32) and del l(qll), the second patient had marker chromosomes der 9, t(9;1) (9pter-.-9q 34:: lqll-lqter) and del 1(qll). Both had 14q+ markers.
The data have been combined with 57 cases with biopsy specimens of non-Burkitt nonHodgkin's lymphoma from the literature. This confirms a frequent numerical involvement of chromosome 7, which was involved in 20% of 63 chromosomally abnormal lymphomas. Chromosome 3 was lost or gained in 19.0% of cases and chromosome X in 17.4%. There was a particularly high rate of structural rearrangement of chromosome 14 (41.2%), with most of these structural changes involving the terminal long-arm band 14q 32. Chromosome 1 was involved in 38.0% of cases, but the abnormalities produced were not specific, and recurrent markers are rare. Abnormalities of chromosome 1 have been found in many malignancies, including the myeloid leukaemias, bladder, ovarian and cervical tumours. Abnormalities of chromosome 14 are rare in the myeloid malignancies and other tumours.
It is still not understood how or why nonrandom changes occur, and there is little experimental evidence to support or direct any theory. Because of the heterogeneous nature of malignancy a unitary approach to the problem of chromosomes in malignancies may not be warranted. It would seem that in cases such as the Philadelphia chromosome of chronic myeloid leukaemia and translocations involving chromosome 14 in the lymphoid malignancies, these particular changes in karyotype are an essential early step. Possibly the more random elements of chromosome change are the result of evolution to suit a particular and precise microenvironment. PROGRESS in the chemotherapy of lymphomas is restricted by the toxicity of presently available drugs and the intrinsic or acquired resistance that some lymphomas may display towards them. An understanding of the mechanisms of action of these compounds illustrates that this toxicity is a reflection of poor selectivity between the effects on tumour cells and host tissues. Antimetabolites have only recently been evaluated for lymphoma treatment, but these compounds are particularly accessible to biochemical study and therefore to scientific therapeutic manipulation. Early studies with the COMLA regime, that incorporates the simultaneous administration of methotrexate (MTX) and cytosine arabinoside (Ara-C) followed by folinic acid, have produced a significant rate of complete and durable remissions in diffuse histiocytic lymphoma. HowNever, experimental studies indicate that writh simultaneous administration of MTX and Ara-C, these drugs can be antagonistic, whereas synergism is obtained if Ara-C is used before MTX. Exposure to MTX decreases utilization of dUMP, with a consequent accumulation of dCTP. The latter competes with the active metabolite of Ara-C, AraCTP, thereby decreasing inhibition of DNA polymerase. It would be of interest to conduct clinical trials of the COMLA regime in w%rhich Ara-C is administered prior to, not concurrently with, MTX. Experimentally it has been shown that the reversal of MTX toxicitv with foliniic acid can be improved upon wNith the use of combinations of purine and pyrimidine nucleosides, since such nucleoside "rescue" appears to have greater selectivity for host tissues. Phase I clinical trials have confirmed that nucleosides protect against MTX toxicity, and Phase II studies nowi in progress should include evaluation of this technique against lymphomas. The use of rescue techniques and the development of less toxic analogues of existing drugs may improve the therapeutic index of anti-lymphoma therapy, but the most promising approach to selective chemotherapy is the rational design of news antimetabolites directed at defined enzyme loci. The 2 enzymes adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) are logical targets to select for inhibition, since their congenital absence leads to selective elimination of lymphocytes. Furthermore, ADA activity is greatly increased in some lymphoid malignancies. Clinical trials of the ADA inhibitor 2'-deoxycoformycin have confirmed activity against lymphomas, particularly of T-cell type. Research is continuing to identify a suitable inhibitor of PNP. Such exploitation of knowledge derived from the study of inborn errors of metabolism affords a new approach to the selective chemotherapy of lymphomas.
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